Association of Checkpoint Inhibitors With Survival in Advanced Non–Small Cell Lung Carcinoma

This systematic review and meta-analysis of 5 randomized clinical trials determines the efficacy of checkpoint inhibitors compared with docetaxel as a second-line therapy for advanced non–small cell lung carcinoma.

from Cancer via ola Kala on Inoreader http://ift.tt/2zbPxqI
via IFTTT